Magle

Magle Group is a Swedish healthcare company that operates as both a contract development and manufacturing organization (CDMO) and a developer of proprietary medical technologies. The company's core technology is the patented Degradable Starch Microspheres (DSM) platform, which is utilized in surgical hemostasis, wound care, and drug delivery applications. Magle provides end-to-end CDMO services specializing in small molecules and complex chemical synthesis from its GMP-certified facilities. Following the 2024 acquisition of Amniotics AB, the group has expanded its portfolio into regenerative medicine and cell therapies derived from amniotic fluid. The company is publicly traded and maintains a global presence through strategic partnerships with major medical device and pharmaceutical firms.